JP7438119B2 - 細胞外小胞関連疾患のための材料および方法 - Google Patents

細胞外小胞関連疾患のための材料および方法 Download PDF

Info

Publication number
JP7438119B2
JP7438119B2 JP2020542716A JP2020542716A JP7438119B2 JP 7438119 B2 JP7438119 B2 JP 7438119B2 JP 2020542716 A JP2020542716 A JP 2020542716A JP 2020542716 A JP2020542716 A JP 2020542716A JP 7438119 B2 JP7438119 B2 JP 7438119B2
Authority
JP
Japan
Prior art keywords
sortilin
composition
cells
dimerization
flag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500078A5 (https=
JP2021500078A (ja
Inventor
晋介 伊藤
エレナ アイカワ
眞範 相川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2021500078A publication Critical patent/JP2021500078A/ja
Publication of JP2021500078A5 publication Critical patent/JP2021500078A5/ja
Application granted granted Critical
Publication of JP7438119B2 publication Critical patent/JP7438119B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7057—(Intracellular) signaling and trafficking pathways
    • G01N2800/7061—Endoplasmic reticulum to Golgi trafficking

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
JP2020542716A 2017-10-23 2018-10-23 細胞外小胞関連疾患のための材料および方法 Active JP7438119B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575762P 2017-10-23 2017-10-23
US62/575,762 2017-10-23
PCT/US2018/057016 WO2019083944A2 (en) 2017-10-23 2018-10-23 MATERIALS AND METHODS FOR DISEASES ASSOCIATED WITH EXTRACELLULAR VESICLES

Publications (3)

Publication Number Publication Date
JP2021500078A JP2021500078A (ja) 2021-01-07
JP2021500078A5 JP2021500078A5 (https=) 2021-10-14
JP7438119B2 true JP7438119B2 (ja) 2024-02-26

Family

ID=66247653

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542716A Active JP7438119B2 (ja) 2017-10-23 2018-10-23 細胞外小胞関連疾患のための材料および方法

Country Status (3)

Country Link
US (2) US11833187B2 (https=)
JP (1) JP7438119B2 (https=)
WO (1) WO2019083944A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
JP2011518791A (ja) 2008-04-27 2011-06-30 ハー・ルンドベック・アクチエゼルスカベット ソルチリンに対する特異的リガンドの設計
US20110166032A1 (en) 2008-04-27 2011-07-07 H. Lundbeck A/S Design and Use of Sortilin Specific Molecular Imaging Ligands
US20160060346A1 (en) 2006-12-21 2016-03-03 H. Lundbeck A/S Modulation of Activity of Proneurotrophins
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
US20170014476A1 (en) 2009-06-10 2017-01-19 Aarhus Universitet SorCS1 for the Treatment of Obesity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
US20160060346A1 (en) 2006-12-21 2016-03-03 H. Lundbeck A/S Modulation of Activity of Proneurotrophins
JP2011518791A (ja) 2008-04-27 2011-06-30 ハー・ルンドベック・アクチエゼルスカベット ソルチリンに対する特異的リガンドの設計
US20110166032A1 (en) 2008-04-27 2011-07-07 H. Lundbeck A/S Design and Use of Sortilin Specific Molecular Imaging Ligands
US20170014476A1 (en) 2009-06-10 2017-01-19 Aarhus Universitet SorCS1 for the Treatment of Obesity
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Guido Hermey，The Vps10p-domain receptor family，Cell. Mol. Life Sci.，2009年，Vol.66，pp.2677-2689
Peter J. McCormick et al.，Palmitoylation Controls Recycling in Lysosomal Sorting and Trafficking，Traffic. Author manuscript，2012年，pp.1-22
Uffe B. Westergaard et al.，Functional Organization of the Sortilin Vps10p Domain，THE JOURNAL OF BIOLOGICAL CHEMISTRY，2004年，Vol. 279, No. 48，pp. 50221-50229

Also Published As

Publication number Publication date
US20240238371A1 (en) 2024-07-18
US20200330553A1 (en) 2020-10-22
US11833187B2 (en) 2023-12-05
WO2019083944A2 (en) 2019-05-02
WO2019083944A3 (en) 2020-04-02
JP2021500078A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
Schartner et al. Dihydropyridine receptor (DHPR, CACNA1S) congenital myopathy
Vanlandewijck et al. Functional characterization of germline mutations in PDGFB and PDGFRB in primary familial brain calcification
Shin et al. Mesenchymal stem cells enhance autophagy and increase β-amyloid clearance in Alzheimer disease models
Haslund et al. Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema
Shi et al. Identification of CHIP as a novel causative gene for autosomal recessive cerebellar ataxia
KR102003571B1 (ko) 골형성 촉진제
Stattin et al. SNX10 gene mutation leading to osteopetrosis with dysfunctional osteoclasts
US11274306B2 (en) Method for inhibiting calcification of a smooth muscle cell (SMC)
KR100553300B1 (ko) 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
Chernyaeva et al. Reduced binding of apoE4 to complement factor H promotes amyloid‐β oligomerization and neuroinflammation
US20240238371A1 (en) Materials and methods for extracellular vesicle-associated diseases
Ng et al. Sugar transporter Slc37a2 regulates bone metabolism in mice via a tubular lysosomal network in osteoclasts
CN118834857A (zh) 使用工程化的去泛素化酶探测泛素依赖性细胞过程的组合物和方法
Noda et al. Optimization of PTH/PTHrP Hybrid Peptides to Derive a Long Acting PTH Analog (LA PTH)
Wang et al. Endothelial genetic deletion of CD147 induces changes in the dual function of the blood‐brain barrier and is implicated in Alzheimer’s disease
JP2008505307A (ja) ＨＡＵＳＰ−Ｍｄｍ２相互作用及びその使用
TW200831536A (en) Method of diagnosing and treating glioma
US20080020461A1 (en) Kinesin-like proteins and methods of use
JP2008517931A (ja) 脂質関連疾患および障害を処置するための、ＰＧＣ−１βを調節するための方法および組成物
TW200831898A (en) Treatment of insulin resistance
Jiang et al. USP34 attenuates cartilage degradation in temporomandibular joint osteoarthritis by ANT1-mediated mitophagy
JP2012167017A (ja) ペプチドおよびその用途
US8101158B1 (en) Methods for treating cerebrovascular disease comprising administering an agent that inhibits prokineticin receptor activity
Masato et al. DOPAL initiates αSynuclein-mediated impaired proteostasis in neuronal projections leading to enhanced vulnerability in Parkinson’s disease
JP4270976B2 (ja) アルツハイマー病治療薬のスクリーニング方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200623

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230524

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240213

R150 Certificate of patent or registration of utility model

Ref document number: 7438119

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150